Wall Street brokerages expect that Stryker Co. (NYSE:SYK) will report sales of $3.20 billion for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Stryker’s earnings, with the lowest sales estimate coming in at $3.15 billion and the highest estimate coming in at $3.24 billion. Stryker reported sales of $2.96 billion in the same quarter last year, which indicates a positive year over year growth rate of 8.1%. The firm is expected to announce its next quarterly earnings results on Tuesday, April 24th.
On average, analysts expect that Stryker will report full year sales of $3.20 billion for the current year, with estimates ranging from $13.32 billion to $13.67 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $14.40 billion per share, with estimates ranging from $14.22 billion to $14.56 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the company earned $1.78 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year.
Stryker (NYSE:SYK) traded down $0.74 during trading on Friday, reaching $166.38. 736,727 shares of the company were exchanged, compared to its average volume of 1,480,000. Stryker has a 1 year low of $129.82 and a 1 year high of $170.00. The firm has a market cap of $62,330.00, a PE ratio of 33.96, a P/E/G ratio of 2.41 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 annualized dividend and a yield of 1.13%. Stryker’s dividend payout ratio (DPR) is presently 38.37%.
In other news, VP William E. Berry, Jr. sold 1,306 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,611 shares of company stock worth $7,178,719. 7.40% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the company. Chemical Bank boosted its position in shares of Stryker by 24.1% during the 4th quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock valued at $2,003,000 after acquiring an additional 2,515 shares during the last quarter. Green Square Capital LLC boosted its position in shares of Stryker by 148.5% during the 4th quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock valued at $871,000 after acquiring an additional 3,350 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in shares of Stryker by 7.8% during the 4th quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after acquiring an additional 385 shares during the last quarter. Colonial Trust Advisors boosted its position in shares of Stryker by 40.9% during the 4th quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock valued at $5,246,000 after acquiring an additional 9,836 shares during the last quarter. Finally, Xact Kapitalforvaltning AB boosted its position in shares of Stryker by 7.3% during the 4th quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock valued at $8,909,000 after acquiring an additional 3,912 shares during the last quarter. 75.71% of the stock is currently owned by hedge funds and other institutional investors.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.